The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark longitudinal study launched in 2004 to define the progression of [Alzheimer's Disease](/diseases/alzheimers-disease) by integrating multimodal neuroimaging with clinical and biomarker data. ADNI has become one of the most influential datasets in neuroscience, with over 10,000 publications citing the study.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark longitudinal study launched in 2004 to define the progression of [Alzheimer's Disease](/diseases/alzheimers-disease) by integrating multimodal neuroimaging with clinical and biomarker data. ADNI has become one of the most influential datasets in neuroscience, with over 10,000 publications citing the study.
Study Design
Phases
ADNI has progressed through multiple phases:
ADNI-1 (2004-2009): Initial cohort of 400 subjects
ADNI established the temporal ordering of biomarker changes in AD:[@jack2010]
Amyloid accumulation (earliest)
Neurodegeneration (CSF tau)
Brain atrophy on MRI
Cognitive decline
Disease Progression
The study has defined the natural history of [MCI due to AD](/diseases/mild-cognitive-impairment):[@veitch2019]
Conversion rates from MCI to AD
Predictors of progression
Role of amyloid and tau
Clinical Trials
ADNI has transformed clinical trial design by:[@weiner2013]
Enrichment strategies using biomarkers
Outcome measures validation
Sample size calculations
Brain Atrophy Patterns
Longitudinal MRI has revealed characteristic patterns of brain atrophy in AD, particularly in the [hippocampus](/brain-regions/hippocampus) and entorhinal cortex. [@jane2018]
Prediction Models
Data support machine learning models for predicting progression from MCI to AD, integrating imaging, genetic, and biomarker data. [@muirhead2020]
Impact on the Field
ADNI has had transformative impact:[@sabuncu2021]
Established standardized imaging protocols
Enabled biomarker validation
Supported drug development
Created open-access data resources
Data Access
ADNI data are freely available to qualified researchers:[@adni2024]
Petersen RC, et al, Alzheimer's Disease Neuroimaging Initiative: Progress report and ADE4 wound management status (2009)
Weiner MW, et al, Alzheimer's Disease Neuroimaging Initiative: Methods and early results (2010)
Weiner MW, et al, The Alzheimer's Disease Neuroimaging Initiative: 2012 update (2012)
Weiner MW, et al, 2013 Update on the Alzheimer's Disease Neuroimaging Initiative (2013)
Veitch DP, et al, Understanding disease progression and improving Alzheimer's disease clinical trials with biomarkers (2019)
Unknown, ADNI Official Website (2024)
Muirhead GT, et al, Global clinical working memory score predicts amyloid burden in preclinical AD (2020)
Jack CR Jr, et al, Hypothetical model of dynamic biomarkers for MCI due to AD (2010)
Jane Costello E, et al, Association of MRI measures with neuropathological measures of AD (2018)
Sabuncu MR, et al, Data from the Alzheimer's Disease Neuroimaging Initiative: 10 years of open data (2021)
Pathway Diagram
The following diagram shows the key molecular relationships involving Alzheimer's Disease Neuroimaging Initiative (ADNI) discovered through SciDEX knowledge graph analysis: